Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Daiichi Sankyo Terminates Charleston Labs Hydrocodone Pact | Contract Pharma

What are you searching for?

Sign in
Collaborations & Alliances

Daiichi Sankyo Terminates Charleston Labs Hydrocodone Pact

Plans to refocus commercial efforts on current product line in the U.S. pain franchise

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Daiichi Sankyo Co., Ltd. has elected to terminate its 2014 development and commercialization agreement with Charleston Laboratories, forgoing further development of Charleston’s hydrocodone products, including CL-108 (hydrocodone, acetaminophen, promethazine) and will be returning all rights to those products to Charleston.
 
“During a recent portfolio and U.S. market review, Daiichi Sankyo made the strategic decision to refocus our commercial efforts on our current product line in the U.S. pain franchise as well as other molecules in our pipeline,” said Ken Keller, president, Administrative and Commercial, Daiichi Sankyo, Inc. “We would like to thank Charleston Laboratories for its partnership and commitment to patients suffering with acute pain and opioid-induced nausea and vomiting.  Daiichi Sankyo remains dedicated to bringing innovative medicines to patients and will continue to explore future opportunities that support our corporate strategy to expand our business and achieve long-term growth.”

Daiichi Sankyo Co., Ltd. will take an impaired loss of approximately $250 million U in the 2Q17, reflecting payments made to Charleston Laboratories under the terms of the agreement.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics